Abstract

TRIMETAZIDINE INDUCED SWEET SYNDROME: A CASE REPORT

Marut Amrutiya, Jinal Divekar, Sapna Gupta and Supriya Malhotra*

.

Abstract

Sweet Syndrome (SS) is a severe form of acute inflammatory neutrophilic dermatosis that manifests as painful erythematous lesions on the skin. It is characterized by the sudden onset of well-defined tender plaques or nodules accompanied by fever, arthralgias, ocular inflammation, headaches, and, rarely, oral, or genital lesions. There are five categories for it and less than 5% of all SS cases come from the last category, which is Drug Induced. Drug induced Sweet Syndrome (DISS) is a well-known entity, with Granulocyte colony stimulating factor (G-CSF) being the most common drug. For diagnosing it, sudden onset eruption of tender, painful plaques, or nodules, and neutrophilic infiltrate in the dermis without vasculitis must be present. Stopping the drug that caused the DISS is the primary method of treatment, and this usually causes the lesions to clear up on their own. In this report, we are presenting a suspected case of DISS attributable to Trimetazidine, in a 38 years old female patient after undergoing percutaneous coronary intervention.

Keywords: DISS, Sweet Syndrome, Trimetazidine, Acute Inflammatory Neutrophilic Dermatosis, SS.